Journal
TRANSPLANT INFECTIOUS DISEASE
Volume 14, Issue 1, Pages 95-98Publisher
WILEY
DOI: 10.1111/j.1399-3062.2011.00659.x
Keywords
hepatitis B virus; HBV reactivation; tenofovir; entecavir; allogeneic hematopoietic stem cell transplant
Categories
Ask authors/readers for more resources
Prophylaxis with lamivudine (LAM) is recommended for hepatitis B core antibody-positive allogenic hematopoietic stem cell transplant (HSCT) recipients, but the optimal timing for the institution and duration of the prophylaxis is still unknown. Furthermore, considering the high rate of mortality associated with hepatitis B virus reactivation (HBV-R), the most potent and long-term effective antiviral regimen should be considered. We report here a case of late onset of HBV-R after a long-term prophylaxis with LAM in a patient who underwent HSCTfor non-Hodgkin lymphoma and who was successfully treated with a combination antiviral regimen including entecavir and tenofovir disoproxil fumarate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available